Zymeworks Inc. (ZYME) stock
ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30117% above fair value
$26.24−0.23 (-0.87%)
Close on Nov 13, 2026Market cap $1.86BP/E 50.5Yield –
Zymeworks operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Zymeworks's operating cash flow for the twelve months ending Sep 30, 2026 was -$111.96M. For fiscal 2025 it was -$33.01M. The highest annual figure on record is $144.11M in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$33.01M | – |
| FY2024 | Dec 31, 2024 | -$110.06M | – |
| FY2023 | Dec 31, 2023 | -$118.32M | -182.1% |
| FY2022 | Dec 31, 2022 | $144.11M | – |
| FY2021 | Dec 31, 2021 | -$192.45M | – |
| FY2020 | Dec 31, 2020 | -$151.40M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$24.04M | – |
| Q2 FY2026 | Jun 30, 2026 | -$31.95M | -364.6% |
| Q1 FY2026 | Mar 31, 2026 | -$45.72M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.26M | – |
| Q3 FY2025 | Sep 30, 2025 | -$31.41M | – |
| Q2 FY2025 | Jun 30, 2025 | $12.07M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.41M | – |
| Q4 FY2024 | Dec 31, 2024 | -$41.51M | -397.9% |
| Q3 FY2024 | Sep 30, 2024 | -$5.88M | – |
| Q2 FY2024 | Jun 30, 2024 | -$24.99M | – |
| Q1 FY2024 | Mar 31, 2024 | -$37.68M | – |
| Q4 FY2023 | Dec 31, 2023 | $13.93M | -95.7% |
| Q3 FY2023 | Sep 30, 2023 | -$42.67M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.40M | – |
| Q1 FY2023 | Mar 31, 2023 | -$83.19M | – |
| Q4 FY2022 | Dec 31, 2022 | $327.36M | – |
| Q3 FY2022 | Sep 30, 2022 | -$73.02M | – |
| Q2 FY2022 | Jun 30, 2022 | -$54.82M | – |
| Q1 FY2022 | Mar 31, 2022 | -$55.41M | – |
| Q4 FY2021 | Dec 31, 2021 | -$50.51M | – |
See a number that looks wrong?